PTC Therapeutics (PTCT)

Common Shares

Sell: $75.75|Buy: $80.00|Change: 0.23 (-0.30%)

Open

$75.96

Previous close

$76.19

Trade high

$76.98

Volume

961,811

Year high

$87.50

Year low

$35.95

Dividend yield

–

Market capitalisation

$6.13 bn

P/E ratio

8.86

ISIN

US69366J2006

This share can be held in a Dealing account Stocks and shares ISA Lifetime ISA JISA

Share price

Performance 31/12/2025

1D | 1M | 3M | 1Y | 3Y ann | 5Y ann | 10Y ann

	Total return (%)
PTC Therapeutics	- 0.30
More...

Company profile

PTC Therapeutics Inc is a biopharmaceutical company that discovers, develops and commercializes clinically differentiated medicines that provide benefits to children and adults living with rare disorders. Its diversified therapeutic portfolio that includes several commercial products and product candidates in various stages of development, including discovery, research and clinical stages, focused on the development of new treatments for multiple therapeutic areas for rare diseases relating to neurology and metabolism. The Company views its operations and manages its business in one operating segment: life science.

Sector

Healthcare

AJ Bell Management Limited (company number 03948391), AJ Bell Securities Limited (company number 02723420) and AJ Bell Asset Management Limited (company number 09742568) are authorised and regulated by the Financial Conduct Authority. All companies are registered in England and Wales at 4 Exchange Quay, Salford Quays, Manchester M5 3EE. See website for full details. AJ Bell procures the provision of the Morningstar Licensed Tools on an “as is” basis and does not guarantee the performance of or accept liability for the Licensed Tools. To the maximum extent permitted by law, AJ Bell excludes liability for the Licensed Tools, including liability for any failure, interruption, delay or defect in the performance of any Licensed Tool, unless it arises as a direct result of the negligence of AJ Bell.